Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big pharma's future: panel discussion

This article was originally published in Scrip

Executive Summary

Big pharma companies are expected to turn a corner in 2016, when the decline in prescription drug revenues should stem, with a return to annual growth then forecast. This is the finding of a new report, The Outlook for Big Pharma, published by Datamonitor Healthcare, in which revenues from a group of 16 top big pharma companies are forecast to grow from $439bn in 2014 to $499bn in 2024.

You may also be interested in...



Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.

Strides Readies SteriScience For Injectables Push

Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.

QUOTED. 18 September 2020. Ed Israelski.

The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel